content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): January 9, 2006
                                                            ---------------
  
                                 CYTOGEN CORPORATION
  
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
            Delaware                       000-14879               22-2322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  -----------------------------------------------------------     ----------------
          (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  <PAGE>
  
  
  ITEM 2.02    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
  
  
       On January 9, 2006, Cytogen Corporation announced its preliminary financial
  results for the year ended  December 31,  2005.  The full text of the January 9,
  2006 press release  issued in connection  with the  announcement  is attached as
  Exhibit 99.1 to this Current Report on Form 8-K.
  
       The information in this Form 8-K and the exhibit  attached hereto shall not
  be deemed "filed" for purposes of Section 18 of the  Securities  Exchange Act of
  1934 (the  "Exchange  Act") or  otherwise  subject  to the  liabilities  of that
  section,  nor shall it be deemed  incorporated  by reference in any filing under
  the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
  specific reference in such a filing.
  
  ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.     Description
        -----------     -----------
  
          99.1          Press Release of Cytogen Corporation dated January 9, 2006
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   January 9, 2006
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
        Exhibit No.     Description
        -----------     -----------
  
          99.1          Press Release of Cytogen Corporation dated January 9, 2006
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8-k_010906.txt", "description": "FORM 8-K FILED ON 01/09/06", "secsgml_size_bytes": 4120}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "06517959"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): January 9, 2006
                                                            ---------------
  
                                 CYTOGEN CORPORATION
  
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                       000-14879               22-2322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  -----------------------------------------------------------     ----------------
          (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 2.02    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
  
       On January 9, 2006, Cytogen Corporation announced its preliminary financial
  results for the year ended  December 31,  2005.  The full text of the January 9,
  2006 press release  issued in connection  with the  announcement  is attached as
  Exhibit 99.1 to this Current Report on Form 8-K.
  
       The information in this Form 8-K and the exhibit  attached hereto shall not
  be deemed "filed" for purposes of Section 18 of the  Securities  Exchange Act of
  1934 (the  "Exchange  Act") or  otherwise  subject  to the  liabilities  of that
  section,  nor shall it be deemed  incorporated  by reference in any filing under
  the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
  specific reference in such a filing.
  
  ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.     Description
        -----------     -----------
  
          99.1          Press Release of Cytogen Corporation dated January 9, 2006
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   January 9, 2006
  EXHIBIT INDEX
  
        Exhibit No.     Description
        -----------     -----------
  
          99.1          Press Release of Cytogen Corporation dated January 9, 2006